Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens. This is an ASCO Meeting Abstract from the 2016 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results